Introduction
Angiogenesis is essential for the growth of many tumors and metastases. Recent studies have demonstrated that human glioblastoma (World Health Organization (WHO) grade IV glioma) overexpresses proangiogenic factors, including vascular endothelial growth factor (VEGF) [1, 2] . VEGF binds to VEGF receptor 1 (VEGFR1, Fms-like-tyrosine kinase (Flt-1)) and VEGFR2 (kinase domain region (KDR), Flk-1), which may activate endothelial cell proliferation, migration and survival [3, 4] . It has been shown that VEGF receptors (VEGFRs) are over-expressed in both grade IV glioma vasculature and grade IV glioma cells [5] . Previous studies demonstrated that VEGF and its corresponding receptor Flk-1 are significant prognostic factors for overall survival in patients with glioma [6, 7] . Therefore, in vivo imaging of VEGFR expression may be useful for tumor diagnosis and monitoring of response to anti-VEGF/VEGFR therapy [4, 8] . For imaging of VEGFR expression, VEGF has been labeled with various radioisotopes [9] [10] [11] [12] . However, to our best knowledge, all these studies were experimental and results of clinical studies are not available. A recent imaging study assessing tumor uptake of a radiolabeled anti-VEGF antibody, such as the monoclonal antibody bevacizumab in glioma, showed unsatisfactory results with significant inter-and intra-patient heterogeneity [13] . The antiangiogenic treatment with bevacizumab has been a major research focus for patients with recurrent and newly diagnosed malignant gliomas in recent years [14] . However, results of interventional trials with bevacizumab have been disappointing [14, 15] . Therefore, it is very important to identify and validate reliable biomarkers for optimization of antiangiogenic therapy for individual patients; VEGFRs could be valuable imaging targets in the course of antiangiogenic therapy. Up to now, no data are available on the imaging of human brain tumors using the radiolabeled VEGF. Based on our previous studies [16] [17] [18] , in this prospective study we evaluated for the first time the prognostic role of [ 
Methods

Patients
Between March 2005 and April 2008, 23 patients with a newly diagnosed primary brain tumor or with a recurrent brain tumor (9 women and 14 men aged 30-83 years, mean age 56.6 ± 14.4 years) were included in this prospective study (Table 1) . Patients with metastatic brain tumors were not considered for participation in the study. Inclusion criteria were initial radiological diagnosis of a primary intra-axial brain tumor or suspected recurrence or progression after treatment of a histologically confirmed intra-axial primary brain tumor. Tumor diagnosis was established by the local neuropathology team according to the WHO classification of tumors of the central nervous system within our study period [19, 20] . This prospective trial was approved by the ethics committee of the Medical University of Vienna. The written informed consents were obtained from all patients. None of the patients had signs of clinically apparent inflammation or infection at the time of the study.
VEGF synthesis and SPECT imaging
Recombinant human VEGF 165 (rhVEGF 165 ) (PromoCell GmbH, Heidelberg, Germany) was labelled with 123 I by the method described previously [17] with a radiochemical purity higher than 97%.
[
123 I]-VEGF was administered slowly as a single intravenous bolus injection over 2 min in an average dose of 140±16 MBq [≤130 pmol (≤5 μg) VEGF per patient]. In order to determine the hemodynamic effects of VEGF, blood pressure and heart rate were monitored during tracer application and scintigraphy. The patients received 200 mg sodium perchlorate three times daily over 3 days for thyroid blockage.
All acquisitions were obtained with double-headed and large field of view camera (Millennium VG with Hawkeye; GE Medical Systems, Milwaukee, Wisc., USA) employing medium-energy high-resolution collimators [21] . Dynamic acquisition of the head was initiated immediately after intravenous administration of [ 
SPECT data analysis
Raw imaging data were reconstructed using the Butterworthfiltered back projection algorithm, generating tomographic views of the brain in the three planes (transverse, coronal, and sagittal). Radiotracer accumulation in the brain tumor was firstly assessed visually. For the calculation of the tumor-to-normal brain uptake (the T/N ratio), a region of interest (ROI) was manually drawn around the lesion on the transverse slice-with close reference to the corresponding MRI/CT slice-and a reference region was drawn on the contralateral tumor-free brain side. The maximum count rate in the lesion ROI and the mean count rate in the reference ROI were used for calculation the T/N ratio according to a previous publication [22] .
Scintigraphic results from the [ 123 I]-VEGF scans were directly compared with consecutive histopathological analyses, which were used as gold standard. MRI and CT were used for lesion allocation as available. C]-MET was produced by the method described previously by Mitterhauser et al. [23] with a radiochemical purity higher than 97%. For PET acquisition, a dedicated full-ring GE Advance PET scanner (General Electric Medical Systems) was used for all patients (field of view: 14.875 cm, 35 slices per PET examination with a slice thickness of 4.25 mm). An average dose of 750 ± 66 MBq MET was intravenously injected 20 min prior to the PET start. Data acquisition was undertaken for another 15 min in 3D mode. A transmission scan for attenuation correction was performed afterwards. Subsequently, the image reconstruction was done by filtered back projection using a Hanning filter with a cutoff value of 6.2 mm and a 128 × 128 matrix.
C]-MET PET data analysis
All reconstructed PET data were transferred from the GE system and evaluated by experienced nuclear medicine physicians using a dedicated Hermes software (Gold 3 Hermes Hybrid Viewer, Hermes Medical Solutions). For visual assessment, brain tumors were analyzed for hypo-, iso-, or hypermetabolism of MET, as described previously [24] . Hypo-or isometabolism of brain tumors was summarized as MET-negative brain tumors. For semiquantitative analysis, cuboid VOIs (20 mm × 20 mm × 20 mm) were manually generated containing the highest tracer uptake of (Fig. 1) The mean diameter of tumors in VEGF scan negative patients was 3.6 ± 1.8 cm (range 1.5-7.0 cm), while in VEGF scan positive patients the mean diameter of tumors was 4.3 ± 1.6 cm (range 1.7-7.0 cm). There was no significant difference in the mean tumor size between VEGF positive tumors and VEGF negative tumors (P = 0.333).
There was a significant correlation between the [ The T/N ratio before radiation therapy was 2.80, whereas the T/N ratio after radiation therapy was 1.78 (Fig. 2) . Comparison of the mean survival days between patients with positive VEGF scan results and patients with negative VEGF scan results showed that there were significant differences (P = 0.003) in mean OS between the patients with positive VEGF scans (315 ± 365 days) and the patients with negative VEGF scans (2020 ± 1768 days) ( Table 1) .
For separating grade IV glioma from other brain tumors a T/N ratio threshold of 1.32 in [ 123 I]-VEGF SPECT at 18 h post injection was identified by ROC analysis (area under the cure (AUC): 0.951, sensitivity 88%, specificity 100%). Significant OS difference was shown using the T/N ratio of 1.32 (T/N ratio < 1.32: 2680 days; T/N ratio > 1.32: 295 days, P = 0.002) (Fig.3 ). 14/16 grade IV gliomas had a T/N ratio of >1.32. Only two grade IV gliomas had T/N ratio of <1.32. All other brain tumors had a T/N ratio of <1.26 in [ [25] supports our results. Chan et al. [25] have demonstrated that overexpression of both VEGFR1 and VEGFR2 was found in the tumor vasculature of grade IV glioma; whereas a weak or no expression of VEGFRs was found in the astrocytomas of grade II, anaplastic astrocytomas, and oligodendroglioma tumors. Therefore, the low number or absence of VEGF receptors may explain negative scintigraphic results in patients with grade II or III glioma or B cell lymphoma. Thus, [ ]-VEGF uptake in the tumor region after radiation therapy. It is too early to make valid conclusions based on these two cases; however, the results appear to have implications for evaluation of therapy response.
The other patient had a tumor with only 1.5 cm diameter, which could be attributed to the limited spatial resolution of our gamma camera. In general, there was no significant difference in mean tumor size between patients with positive and negative [ In the present prospective study, we explored the ability of [ prognostic impact in treatment-naïve gliomas [24] . Despite a modest number of patients examined with [ 11 C]-MET PET, the results of our present study were consistent with previous publications [24, 27] .
Interestingly, two patients with grade II or III glioma had negative [ The effect of VEGF on tumor growth was not investigated in the present study. It has been reported that intratumoral administration of exogenous VEGF in a murine fibrosarcoma model did not significantly change tumor weight and size as compared to saline controls [28] . In our studies, the concentration of injected VEGF is far below pharmacologically relevant doses and, thus, very unlikely to promote tumor growth. Even therapeutic clinical trials of VEGF delivery at pharmacologic doses in peripheral vascular or coronary disease failed to significantly increase angiogenesis [29] .
The in vivo stability of radiolabeled tracers is always a concern, such as those based on iodine radioisotopes. Analysis of the chemical status of plasma radioactivity in the samples of the first 30 min after injection mainly shows VEGF-bound radioiodine in the form of the original [ There are some limitations of the present study. Firstly, a limited number of patients with grade 2 or 3 glioma were included and furthermore metastatic brain tumors were not included in the present study. Previous studies [5] [6] [7] have demonstrated increased (tumor) angiogenesis in grade IV glioma in vitro, exploring the value of [ 123 I]-VEGF for imaging the (tumor) angiogenesis of grade IV glioma would be very interesting; therefore, more patients with verified or suspect grade IV glioma were included in this prospective pilot study. Secondly, we have performed the SPECT examinations only at 30 min and 18 h post injection. The design of this prospective clinical trial was made based on our previous studies of different tumors [17, 18] and we expected a similar distribution. In the present study, significant accumulation of [ 
Conclusion
